CRISPR-Based Delivery System Generates CAR T Cells In Vivo

A two-vector delivery system generates tumor-targeting CAR T cells directly inside the body, achieving complete responses in mouse cancer models

October 13, 2026
3 min

The Medicine Maker

At a Glance

Category	Detail
Condition	In vivo generation of chimeric antigen receptor (CAR) T cells for cancer models
Key Mechanisms	A two-vector system uses enveloped delivery vehicles to transport CRISPR–Cas9 ribonucleoproteins and adeno-associated viruses to deliver DNA templates for insertion of a CAR transgene at the T-cell receptor alpha constant (TRAC) locus.
Target Population	Preclinical models of B-cell acute lymphoblastic leukemia, multiple myeloma, and sarcoma; the approach has not been established for human treatment.
Care Setting	Preclinical research using humanized and tumor-bearing mouse models; further evaluation in larger, immunocompetent animal models is needed before clinical translation.

Key Highlights

The platform aims to generate CAR T cells in vivo, rather than extracting, modifying, and reinfusing a patient's T cells.
The system combines CRISPR–Cas9-carrying enveloped delivery vehicles with AAV-delivered DNA templates and targets insertion to the TRAC locus.
In humanized mouse models, CAR-expressing cells reached up to 19.7% of splenic T cells, with complete B-cell depletion.
Reported complete responses included 18 of 20 mice with B-cell acute lymphoblastic leukemia, all 8 mice with multiple myeloma, and responses in sarcoma-bearing mice.
The authors identify immunogenicity, biodistribution, and safety as unresolved questions because the studies used immunodeficient mouse models.

Guideline-Based Recommendations

Diagnosis

Management

The article describes an experimental in vivo CAR T-cell engineering platform; it does not provide clinical treatment recommendations.

Monitoring & Follow-up

The authors state that further studies should assess immunogenicity, biodistribution, and safety in larger, immunocompetent animal models, including nonhuman primates.

Risks

The immunodeficient mouse models limit assessment of immunogenicity, biodistribution, and safety.
The platform remains preclinical and has not been established for clinical use.

Patient & Prescribing Data

No human patients were treated. The reported studies used humanized and tumor-bearing mouse models of B-cell acute lymphoblastic leukemia, multiple myeloma, and sarcoma.

A single injection produced reported antitumor responses in mouse models. The article provides no human dosing, prescribing, or clinical safety data.

Clinical Best Practices

Interpret the reported efficacy as preclinical evidence from mouse models, not as evidence of established human benefit.
Do not infer clinical safety or suitability from these studies; the authors call for further evaluation in larger, immunocompetent animal models before clinical translation.